Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Monotherapy for Glucose Control in Type 2 Diabetes
NCT00085969Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2003
- Primary completion
- Jan 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c (glycosylated hemoglobin) at Day 28. Started Sep 2003; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00085969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085969.